Rallybio Corporation (NASDAQ:RLYB – Free Report)’s stock is set to reverse split before the market opens on Monday, November 23rd. The 1-2 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, November 19th.
Rallybio Stock Performance
Shares of RLYB opened at $15.26 on Thursday. The company’s 50 day moving average price is $16.43 and its 200 day moving average price is $13.54. Rallybio has a 52 week low of $3.67 and a 52 week high of $17.57. The company has a market capitalization of $82.10 million, a PE ratio of -4.16 and a beta of -0.73.
Rallybio (NASDAQ:RLYB – Get Free Report) last released its quarterly earnings data on Tuesday, October 27th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($1.44) by $0.96. Rallybio had a negative net margin of 911.07% and a negative return on equity of 31.44%.
Rallybio Announces Dividend
Analyst Upgrades and Downgrades
RLYB has been the topic of a number of research reports. Weiss Ratings downgraded shares of Rallybio from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 30th. Wall Street Zen upgraded Rallybio from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has an average rating of “Sell”.
View Our Latest Stock Report on RLYB
Institutional Investors Weigh In On Rallybio
Several large investors have recently made changes to their positions in RLYB. State Street Corp acquired a new stake in shares of Rallybio in the 2nd quarter valued at $208,000. Citadel Advisors LLC bought a new stake in Rallybio in the second quarter worth $1,155,000. ADAR1 Capital Management LLC boosted its holdings in Rallybio by 4,411.1% in the second quarter. ADAR1 Capital Management LLC now owns 926,352 shares of the company’s stock worth $14,822,000 after purchasing an additional 905,817 shares in the last quarter. Finally, BlackRock Inc. boosted its holdings in Rallybio by 73.5% in the second quarter. BlackRock Inc. now owns 30,332 shares of the company’s stock worth $485,000 after purchasing an additional 12,846 shares in the last quarter. Institutional investors own 90.34% of the company’s stock.
Rallybio Company Profile
Rallybio is a clinical-stage biotechnology company focused on developing treatments for people affected by rare and severe diseases. Founded in 2018, the company is based in New Haven, Connecticut, and has concentrated its research and development efforts on conditions with significant unmet medical needs. One of Rallybio’s investigational programs is RLYB212, an antibody being developed to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare condition that can cause dangerously low platelet counts in a fetus or newborn.
See Also
- Five stocks we like better than Rallybio
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.
